A prospective study comparing quantitative Cytomegalovirus(CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Gentile, Giuseppe ^a   Picardi, Alessandra ^b   Capobianchi, Angela ^a   Spagnoli, Alessandra ^b   Cudillo, Laura ^b   Dentamaro, Teresa ^b   Tendas, Andrea ^b   Cupelli, Luca ^b   Ciotti, Marco ^b   Volpi, Antonio ^b   Amadori, Sergio ^b   Martino, Pietro ^a   de Fabritiis, Paolo ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; LEVOFLOXACIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROPATHY; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; LYMPHOMA; MALE; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; SOLID TUMOR; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRAL MATRIX PROTEINS; VIREMIA;

EID: 33845627645     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-167     Document Type: Article

References (39)

1. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L: Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
2. Boeckh M, Nichols WG: Immunosuppressive effects of beta-herpesviruses. Herpes 2003, 10:12-16.
3. Gentile G, Capobianchi A, Ferraironi M, Greco E, Martino P: Relationship of serum human herpesvirus 6 DNA with cytomegalovirus pp65 antigenemia in allogeneic bone marrow transplant recipients. Transplantation 2004, 77:1907-1908.
4. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991, 325:1601-1607.
5. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 1991, 324:1005-1011.
6. Gerna G, Revello MG, Percivalle E, Morina F: Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992, 30:1232-1237.
7. Gerna G, Furione M, Baldanti F, Percivalle E, Comoli P, Locatelli F: Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br J Haematol 1995, 91:674-683.
8. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD: Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992, 80:1358-1364.
9. van den Berg AP, van den Bij W, van Son WJ, Anema J, van der Giessen M, Schirm J, Tegzen AM, The TH: Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation - a report of 130 consecutive patients. Transplantation 1989, 48:991-995.
10. Boeckh M, Gooley TA, Meyerson D, Cunningham T, Schoch G, Bowden RA: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
11. Boeckh M, Bowden RA, Gooley TA, Meyerson D, Corey L: Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999, 93:1781-1782.
12. Boeckh M, Boivin G: Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998, 11:533-554.
13. Mori T, Okamoto S, Matsuoka S, Yajima T, Wakui M, Watanabe R, Ishida A, Iwao Y, Mukai M, Hibi T, Ikeda Y: Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2000, 25:765-769.
14. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J, Wagner S, Muller CA: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995, 86:2815-2820.
15. Cortez KJ, Fischer SH, Fahle GA, Calhoun LB, Childs RW, Barrett AJ, Bennett JE: Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis 2003, 188:967-972.
16. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD: Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
17. Solano C, Munoz I, Gutierrez A, Farga A, Prosper F, Garcia-Conde J, Navarro D, Gimeno C: Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001, 38:3939-3941.
18. Mori T, Okamoto S, Watanabe R, Yamazaki R, Tsukada Y, Nagayama H, Ishida A, Ikeda Y: Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29:777-782.
19. Ikewaki J, Ohtsuka E, Kawano R, Ogata M, Kikuci H, Nasu M: Realtime PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients. J Clin Microbiol 2003, 41:4382-4387.
20. Gerna G, Furione M, Baladanti F, Sarasini A: Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients. J Clin Microbiol 1994, 32:2709-2717.
21. Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, Espy M, Smith TF, Paya CV: The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002, 73:968-973.
22. Limaye AP, Huang ML, Liesenring W, Stensland L, Corey L, Boeckh M: Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis 2001, 183:377-382.
23. Wolf DG, Spector SA: Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993, 56:330-334.
24. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ: Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998, 101:497-502.
25. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997, 64:108-113.
26. Saltzman RL, Quirk MR, Jordan MC: High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest 1992, 90:1832-1838.
27. Ljungman P, Griffiths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
28. Fleiss JL: Statistical methods for rates and proportions. In Wiley series in probability and mathematical statistics Edited by: Bradley RA, Hunter JS, Kendall DG, Watson GS. John Wiley & Sons, Inc., New York; 1981:218.
29. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993, 118:173-178.
30. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR: Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
31. Boivin G, Belanger R, Delage R, Beliveau C, Demers C, Goyette N, Roy J: Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 2000, 38:4356-4360.
32. Gerna G, Zavattoni M, Percivalle E, Grossi P, Torsellini M, Revello MG: Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid organ transplant recipients with primary HCMV infection. J Clin Microbiol 1998, 36:1113-1116.
33. Gerna G, Baldanti F, Lilleri D, Parea M, Torsellini M, Castiglioni B, Vitulo, Pellegrini C, Vigano M, Grossi P, Revello MG: Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation 2003, 75:1012-1019.
34. Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M, De Stefano P, Middeldorp J, Locatelli F, Revello MG: Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Transplantation 2003, 101:5053-5060.
35. Boivin G, Quirk MR, Kringstad BA, Germain M, Jordan C: Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients. Antimicrob Agents Chemother 1997, 41:860-862.
36. Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M: Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction. Bone Marrow Transplant 2002, 29:599-606.
37. Gerna G, Percivalle E, Baldanti F, Sozzani S, Lanzarini P, Genini E, Lilleri D, Revello MG: Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 2000, 74:5629-5638.
38. Kalpoe JS, Kroes AC, de Jong MD, Schinkel J, de Brouwer CS, Beersma MF, Claas EC: Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004, 42:1498-1504.
39. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L: Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004, 42:1142-148.